Mountain Valley MD Announces Publication of Soluvec™ Trial Data in Therapeutic Delivery
Retrieved on:
Thursday, August 10, 2023
Health, Clinical Trials, General Health, Research, Science, Biotechnology, Drug, Human, CSE, Hancock, Pharmacovigilance, Pharmacokinetics, Avermectin, IVM, Livestock, FRA, Solubility, Drug resistance, Republic, Pesticide, Animal, Dog, Water, Knowledge, Key finding attacks, Safety, Ivermectin, Pharmaceutical industry
Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP), a leading-edge publicly traded biotech company whose science includes that of novel solubilization methods for therapeutic compounds, is pleased to announce the recent peer-reviewed publication of the Company’s Soluvec™ study data in the journal, Therapeutic Delivery.
Key Points:
- Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP), a leading-edge publicly traded biotech company whose science includes that of novel solubilization methods for therapeutic compounds, is pleased to announce the recent peer-reviewed publication of the Company’s Soluvec™ study data in the journal, Therapeutic Delivery.
- The published study highlights the benefits of the Company’s patented Soluvec™ formulation, a novel, solvent-free aqueous Ivermectin invention.
- The study confirmed that parenteral administration of Soluvec™ led to an Ivermectin drug exposure approximately seven times higher than traditional oral drug dosing, with greater bioavailability, offering potential for enhanced therapeutic effectiveness.
- Key Findings from the Study:
Improved Solubility with Soluvec™: In the resolubilized product, Soluvec™, Ivermectin was present as a mix of 28.0 nm particles and polysorbate-solubilized free Ivermectin.